Skip to content
HowShorted

ABEONA THERAPEUTICS INC. short interest in 2024

In 2024, ABEONA THERAPEUTICS INC.'s disclosed short interest ran from 2.67% of shares outstanding on 12 Jan 2024 to 5.87% on 31 Dec 2024, a change of +3.20 percentage points. The year's high was 12.28% on 28 Jun 2024 and its low 2.67% on 12 Jan 2024, averaging 7.39% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.75 days on 13 Sep 2024. Full history: ABEONA THERAPEUTICS INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ABEONA THERAPEUTICS INC. in 2024

2024 in figures

Start of year
2.67% (12 Jan 2024)
End of year
5.87% (31 Dec 2024)
Change
+3.20 pp
High
12.28% (28 Jun 2024)
Low
2.67% (12 Jan 2024)
Average
7.39%
Highest days to cover
17.75 (13 Sep 2024)
SEC filings marked
9

Every report in 2024

ABEONA THERAPEUTICS INC. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20242.67%3.01
31 Jan 20243.14%3.51
15 Feb 20246.31%4.19
29 Feb 20246.63%4.53
15 Mar 20246.23%3.77
28 Mar 20247.29%4.7310-K filed, results (8-K)
15 Apr 20247.54%11.33
30 Apr 202412.23%2.21
15 May 202411.04%2.67results (8-K), 10-Q filed, results (8-K)
31 May 20248.36%4.55
14 Jun 20249.69%5.88
28 Jun 202412.28%7.14
15 Jul 202411.26%8.04
31 Jul 202410.85%7.70
15 Aug 20246.99%8.9810-Q filed, results (8-K)
30 Aug 20246.56%11.94
13 Sep 20246.07%17.75
30 Sep 20246.16%9.26
15 Oct 20246.39%10.43
31 Oct 20246.09%12.79
15 Nov 20246.05%7.6310-Q filed, results (8-K)
29 Nov 20245.93%7.41
13 Dec 20245.83%14.58
31 Dec 20245.87%13.92

See also: ABEONA THERAPEUTICS INC.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.